Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
Adding blinatumomab to combination chemotherapy in patients with newly diagnosed childhood standard-risk B-cell ALL of average or higher risk of relapse significantly improved disease-free survival. (Funded by the National Institutes of Health and others; AALL1731 ClinicalTrials.gov number, NCT03914625.).
Authors
- Susan J. Conway (ORCID: https://orcid.org/0000-0002-0577-2312)
- Karen R. Rabin (ORCID: https://orcid.org/0000-0002-4081-8195)
- Mignon L. Loh (ORCID: https://orcid.org/0000-0003-4099-4700)
- Brent Lee Wood (ORCID: https://orcid.org/0000-0001-7414-3969)
- Holly R. Kubaney
- Ilan Kirsch
- Stephen P. Hunger (ORCID: https://orcid.org/0000-0002-5492-3957)
- Gerhard Zugmaier (ORCID: https://orcid.org/0000-0001-6879-2671)
- Mary Shago (ORCID: https://orcid.org/0000-0002-7386-2504)
- Elizabeth A. Raetz (ORCID: https://orcid.org/0000-0002-8547-1658)
- John A. Kairalla (ORCID: https://orcid.org/0009-0005-2430-2921)
- Elizabeth M. Wagner (ORCID: https://orcid.org/0000-0003-0563-6692)
- David T. Teachey (ORCID: https://orcid.org/0000-0001-7373-8987)
- Anne Angiolillo
- Sarah W. Alexander (ORCID: https://orcid.org/0000-0002-9695-1702)
- Tamara P. Miller (ORCID: https://orcid.org/0000-0003-4250-5376)
- Rachel E. Rau (ORCID: https://orcid.org/0000-0003-4096-6603)
- Lia Gore (ORCID: https://orcid.org/0000-0002-2546-4616)
- Olga Militano
- Naomi Joan Winick (ORCID: https://orcid.org/0000-0002-6636-3870)
- Yvonne Moyer
- Amanda M. Li (ORCID: https://orcid.org/0000-0001-8099-9501)
- Jennifer L. McNeer (ORCID: https://orcid.org/0000-0002-4743-6325)
- Shalini C. Reshmi (ORCID: https://orcid.org/0000-0003-1491-077X)
- Maureen M. O’Brien (ORCID: https://orcid.org/0000-0002-9054-4321)
- Andrew J. Carroll (ORCID: https://orcid.org/0000-0001-9844-730X)
- Sumit Gupta (ORCID: https://orcid.org/0000-0003-1334-3670)
- Faraz Zaman (ORCID: https://orcid.org/0000-0002-0758-4630)
- Sue Zupanec (ORCID: https://orcid.org/0000-0003-1755-7203)
- Meenakshi Devidas (ORCID: https://orcid.org/0000-0002-1099-3478)
- Cindy Wang (ORCID: https://orcid.org/0000-0001-5372-2371)
- Maki Okada (ORCID: https://orcid.org/0009-0005-3331-8191)
- Tara Haworth-Wright
Institutions
- Seattle Children's Hospital (US)
- St. Jude Children's Research Hospital (US)
- Nationwide Children's Hospital (US)
- Amgen (United States) (US)
- Primary Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Children's Hospital of Los Angeles (US)
- Emory University (US)
- University of Toronto (CA)
- University of Florida Health (US)
- Toronto General Hospital (CA)
- University of Alabama at Birmingham (US)
- NYU Langone Health (US)
- Fred Hutch Cancer Center (US)
- Children's Hospital Colorado (US)
- Southwestern Medical Center (US)
- Dell Children's Medical Center of Central Texas (US)
- Adaptive Biotechnologies (United States) (US)
- Center for Cancer and Blood Disorders (US)
- Miller Children's & Women's Hospital (US)
- Amgen (Germany) (DE)
- Children's Oncology Group (US)
- Servier (France) (FR)
- Children's Cancer Center (US)
- BC Children's Hospital (CA)
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-12-07
- DOI
- https://doi.org/10.1056/nejmoa2411680
- Citations
- 144
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 78.18
Funders
- St. Baldrick's Foundation
- National Institutes of Health
- National Cancer Institute